Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta/NEUPOGEN, and Enbrel. The company operates in a single segment: human therapeutics.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2005 |
|---|---|---|---|
| Total Revenues | $3,612 | $10,433 | $9,159 |
| Net Income | $1,102 | $2,117 | $2,850 |
| Diluted EPS | $0.94 | $1.77 | $2.26 |
| Operating Cash Flow (9mo) | N/A | $4,147 | $3,782 |
| Cash & Marketable Securities | $5,781 (Sep 30, 2006) | N/A | N/A |
| Total Debt Outstanding | $9,006 (Sep 30, 2006) | N/A | N/A |
Profitability: Operating income for the nine months ended September 30, 2006, was $2,851 million, a decrease from $3,747 million in the prior year period, primarily due to a $1.1 billion write-off of acquired in-process research and development (IPR&D) related to the Abgenix acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 15% for the three months and 14% for the nine months ended September 30, 2006, compared to the prior year. Product sales grew 15% (Q3) and 14% (YTD), driven by demand for Aranesp, Neulasta, and Enbrel.
- Expense Increases:
- R&D Expenses: Increased 55% (Q3) and 40% (YTD) due to higher staff costs, clinical trial funding for late-stage programs (e.g., denosumab), and the adoption of SFAS No. 123(R) requiring stock option expense recognition.
- SG&A Expenses: Increased 23% (Q3) and 24% (YTD) due to higher staff levels, infrastructure costs (ERP system), and increased outside marketing expenses.
- Acquisitions:
- Abgenix: Acquired on April 1, 2006, for approximately $2.1 billion in cash plus assumed debt. Resulted in a $1.1 billion immediate expense for acquired IPR&D in Q2 2006.
- Avidia: Acquired on October 24, 2006 (subsequent event), for approximately $290 million net cash.
- Financing Activity: Issued $5.0 billion in convertible notes (2011 and 2013) in February 2006. Concurrently repurchased $3.0 billion of common stock and purchased $1.5 billion in convertible note hedges. Net proceeds from these combined transactions were $440 million.
Guidance, Outlook, and Risks
- Outlook: Management expects Aranesp, Neulasta, and Enbrel to continue driving year-over-year sales growth for the remainder of 2006. However, maintaining share is expected to be more challenging due to an increasingly competitive environment and share loss with Enbrel. Product sales growth is expected to be lower than in previous years due to the significant sales levels already attained.
- Reimbursement Risks: Sales are heavily dependent on government and private payer reimbursement. The Medicare Modernization Act (MMA) and changes to the Average Sales Price (ASP) methodology could impact sales. The company believes the impact for the remainder of 2006 will not be significant but notes uncertainty regarding future regulations.
- Operational Risks:
- Manufacturing: Significant reliance on the Puerto Rico facility for formulation, fill, and finish of major products. Risks include natural disasters, power failures, and supply chain disruptions.
- Patent Expirations: Principal European patents for erythropoietin and G-CSF have expired, exposing the company to potential biosimilar competition in the EU starting in 2007.
- Clinical Trials: Increased complexity and size of trials (e.g., denosumab) are driving R&D costs. Delays or failures in these trials could adversely affect future product launches.
- Legal Proceedings: Ongoing litigation includes patent disputes (e.g., Roche, TKT), Average Wholesale Price (AWP) litigation, and product liability claims. Management does not believe pending items will have a material adverse effect on financial position, though outcomes could impact quarterly results.
Key Facts for Investor Verification
- Abgenix Integration: Verify the realization of anticipated benefits from the Abgenix acquisition, specifically regarding Vectibix and denosumab royalty elimination, against the $1.1 billion IPR&D write-off.
- Reimbursement Impact: Monitor the actual impact of Medicare Part D and ASP+6% reimbursement changes on EPOGEN and Aranesp sales volumes and pricing power.
- Stock-Based Compensation: Assess the ongoing impact of SFAS No. 123(R) adoption on net income and EPS, with estimated annual stock option expense projected at $0.12 to $0.14 per share for 2006.
- Manufacturing Capacity: Track progress on new manufacturing facilities in Ireland and Puerto Rico to ensure supply meets demand for key products, mitigating risks associated with the single-source Puerto Rico facility.
- Convertible Notes: Review the terms of the $5.0 billion convertible notes issued in 2011 and 2013, including conversion triggers and the associated warrant transactions.